Table 2.
Clinical Characteristics of the Patients With HBV Infection.
| Total (n = 976) | Immune tolerant phase (n = 123) | Immune clearance phase (n = 192) | Low-replicative phase (n = 476) | HBeAg negative phase (n = 185) | ANOVA P-value | |
|---|---|---|---|---|---|---|
| Gender (M/F), n (%) | 667:309 (68:32) | 91:32 (74:26) | 134:58 (70:30) | 317:159 (67:33) | 125:60 (68:32) | – |
| Age, yrs (median, min–max) | 32 (3–82) | 31 (4–75) | 35 (3–70) | 30 (3–76) | 35 (9–82) | <0.009 |
| HBeAg status | Positive | Positive | Negative | Negative | – | |
| ALT, IU/ml (median, 95% CI) | 37 (54–60) | 36 (34–36) | 94 (93–107) | 29 (29–30) | 89 (92–108) | <0.001 |
| AST, IU/ml (median, 95% CI) | 30 (42–47) | 27 (27–31) | 56 (67–81) | 26 (27–29) | 46 (59–72) | <0.001 |
| Bilirubin, μmol/L (median, 95% CI) | 3 (6–7) | 3 (4–7) | 4 (7–8) | 3 (5–6) | 7 (7–9) | <0.001 |
| HBsAg, IU/ml (median, 95% CI) | 1029 (14308–26096) | 41,976 (95484–178562) | 7542 (9713–13765) | 569 (647–820) | 871 (1104–1708) | <0.001 |
| HBsAg, log10 IU/ml (median, 95% CI) | 3.01 (2.98–3.11) | 4.62 (4.28–4.60) | 3.88 (3.76–3.90) | 2.76 (2.33–2.48) | 2.94 (2.91–3.01) | <0.001 |
| HBV DNA IU/ml (median, 95% CI) | 2563 (5.14 × 107 to 1.19 × 108) | 1.01 × 108 (3.49 × 108 to 8.50 × 108) | 5.88 × 106 (2.17 × 107 to 3.62 × 107) | 200 (451–602) | 12,194 (−5.26 × 106 to 4.97 × 107) | <0.001 |
| HBV DNA log10 IU/ml (median, 95% CI) | 3.41 (3.86–4.18) | 8.00 (7.21–7.77) | 6.77 (6.30–6.67) | 2.30 (1.85–2.06) | 4.09 (4.30–4.64) | <0.001 |
HBeAg, hepatitis B early antigen; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBV, hepatitis B virus; HBsAg hepatitis B surface antigen.